Eli Lilly in the NEWS Eli Lilly and Company (LLY) announced detailed results from the SYNERGY-NASH phase 2 study having 190 patients with or without type 2 diabetes to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.  The clinical trial results demonstrated that 51.8%, 62.8% and . . . This content is for …

Akous Inc to Present at the Association for Research in Otolaryngology Akouos, Inc. - a wholly owned subsidiary of Eli Lilly and Company (LLY) announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which restored the hearing within 30 days of AK-OTOF administration in the first participant, with more than a decade history of deep . . . This content is for paid …

Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity is several devastating diseases, which  include  cardiovascular diseases, high blood pressure, Type 2 diabetes, cancers, sleep apnea, breathing problems, and more.  Many studies demonstrated that effective treatments for the disease will treat all these sicknesses.  The good news is that we already have effective treatments. Part of the effective …

FDA Approval of Eli Lilly Product Zepbound for Obesity On Wednesday, Nov. 8, 2023,  the U.S. FDA approved Eli Lilly (LLY) product ZepboundTM (tirzepatide) injection for the treatment of obesity.  Zepbound is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of …

Beam Therapeutics in the NEWS Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to acquire certain rights under . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Our Most Pressing Need Our current, most pressing need is news that makes sense. Stock Market investors are waiting for comprehensive news regarding inflation in the U.S., the rest of the world's economy and the price of crude oil. Indeed, we are all waiting to hear confirmed news promising the end of Russia's invasion into Ukraine. All the news we have been hearing up til …

Prohost Portfolio PLUS #5 Vir Biotechnology Vir Biotechnology (VIR) combines cutting-edge technologies with immunologic insights to prevent and treat serious infectious diseases. Proof of concept and feasibility has been offered as demonstrated in early and mid-trial results; the firm, together with GlaxoSmithKline, have applied for the approval . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vir Biotechnology and GlaxoSmithKline in April 2020  In April 2020, Vir Biotechnology and GlaxoSmithKline entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2 (the virus that causes COVID-19). The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic …

Eli Lilly and AbCellera Collaboration Result LY-C0V555  A lot of discoveries, followed by thorough experimentation beyond the vaccines, are taking place in the biotechnology and large biopharmaceutical companies to defeat COVID-19. The most recently discovered product by AbCellera, which was developed by Eli Lilly (LLY), is LY-CoV555 - a potent, neutralizing IgG1 monoclonal antibody (mAb), directed . . . This content is for paid subscribers. …

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV) as a possible emergency savior . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Stock Market Volatility  Stocks can move up and down for various reasons but not all of them have anything to do with the real value of the firms. As a matter of fact, almost all stocks outperform for a while, reverse their course to underperforming, then restart the cycle. The stock market in its entirety does the same thing for reasons that have nothing to …

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide (CGRP) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen (AMGN . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.  The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s bad is that all the accomplishments could not bring joy to the deserving investors. The reason is the unpersuasive crazy market behavior. We believe that investors’ unrealized profits have not gone with the cruel blowing wind. Investors will soon be bringing in their confiscated profits. We will elaborate on …

Tanezumab, an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all three co-primary endpoints in patients with osteoarthritis (OA). The 16-week Phase 3 study, which evaluated subcutaneous administration of tanezumab in patients with OA, demonstrated that the patients who received two doses of tanezumab, separated by eight weeks, experienced a statistically significant improvement in pain, physical function and patients’ overall assessment …

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY AFTER AMGEN AND TEVA In less than five months, the FDA approved three products belonging to four drug developers – all targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine headache. The latest for Eli Lilly (LLY) last week . . . This content is for paid subscribers. …

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ ears, minds and souls melodies composed by legendary authors, the stock market reflects what’s going on in the world, which would positively or negatively impact the lives and well being of the earth’s residents . . . This content is for paid subscribers. Please click here to subscribe or here to …

The Week in Review #9 KNOCKING DOWN THE BIOTECH STOCKS - Knocking down the biotech companies’ stocks during the announcement of the quarterly reports is no news. Most investors in the stock market, especially those who invest in the biotech sector have become familiar with this pattern . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

It took only a few months after the dosing stages of NKTR-358 in in a Phase I trial for Eli Lilly to strike a deal worth $400 million with the ascending firm Nektar (NKTR) related to the drug. Eli Lilly seemed impressed with NeKtar’s drug, which was designed to treat autoimmune and other chronic inflammatory conditions. NKTR-358 targets interleukin (IL-2) receptor complex. Nektar and Lilly …

GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that can modify the genome in a living cell, providing unprecedented reach that would help the creation of treatments for genetic diseases. The dream about emerging solutions through genome editing techniques, which could correct genetic mutations causing diseases seems to be turning into reality. Among the innovative firms in this …